In addition, METTL1 expression is associated with extremely poor prognosis in KIRC and mesothelioma, while it is related to superior survival in patients with ovarian serous cystadenocarcinoma [56]. This evidence concerns the gene METTL1 and ovarian serous cystadenocarcinoma.